British start-up crowdfunding platforms Crowdcube and Seedrs agreed Thursday, March 25, to terminate their £140 million (US$192 million) merger, a day after regulators raised competition concerns with the deal.
The UK Competition and Markets Authority (CMA) on Wednesday stated that it was inclined to block the deal, claiming it would lead to a “substantial lessening of competition” in the equity crowdfunding space. Were the two businesses to combine, they would control at least 90% of the market, the CMA stated.
Crowdcube and Seedrs first announced plans to merge in October. The two platforms have been used by a number of well-known UK start-ups, including the digital banks Revolut and Monzo, to raise capital without having to tap venture capital or angel investors directly.
But in its provisional findings, the CMA stated the deal “could result in UK SMEs and investors losing out as a result of higher fees and less innovation.”
“The CMA’s initial view is that blocking the merger may be the only way of addressing these competition concerns,” the watchdog added.
Both Crowdcube and Seedrs stated they were disappointed with the CMA’s decision. Crowdcube told CNBC that it could still thrive as an independent business and “remains in a very strong financial position.”
“We continue to invest in our people and products and we expect to be profitable again in the first half of 2021 with an unprecedented level of high profile European businesses set to fundraise with us in the coming weeks,” a spokesperson added.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan